Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children
    Kosecik, Mustafa
    Dervisoglu, Pinar
    Koroglu, Mehmet
    Isguven, Pinar
    Elmas, Bahri
    Demiray, Tayfur
    Altindis, Mustafa
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 228 : 158 - 161
  • [22] Soluble urokinase plasminogen activator receptor (suPAR) and glomerular disease in children: a narrative review
    Phuong Anh Le Thy
    Thuy Yen Hoang Thi
    Kiem Hao Tran
    Huu Son Nguyen
    Egyptian Pediatric Association Gazette, 70
  • [23] Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
    Hoybye, Charlotte
    Faseh, Laia
    Himonakos, Christos
    Pielak, Tomasz
    Eugen-Olsen, Jesper
    ENDOCRINE CONNECTIONS, 2019, 8 (06): : 772 - 779
  • [24] Soluble urokinase type plasminogen activator receptor (suPAR) and mortality in acute pulmonary embolism
    Oblitas, Crhistian-Mario
    Lopez-Rubio, Marina
    Lago-Rodriguez, Marta-Olimpia
    Galeano-Valle, Francisco
    Garcia-Gamiz, Mercedes
    Zamora-Trillo, Angielys
    Walther, Luis-Antonio Alvarez-Sala
    Demelo-Rodriguez, Pablo
    MEDICINA CLINICA, 2024, 163 (06): : 281 - 285
  • [25] Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
    Oezdirik, Burcin
    Stueven, Anna
    Knorr, Jana
    Geisler, Lukas
    Mohr, Raphael
    Demir, Muenevver
    Hellberg, Teresa
    Loosen, Sven H.
    Benz, Fabian
    Wiedenmann, Bertram
    Tacke, Frank
    Wree, Alexander
    Jann, Henning
    Roderburg, Christoph
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
  • [26] The role of soluble urokinase plasminogen activator receptor (SuPAR) as an indicator of the severity of acute pancreatitis
    Kucukceran, Kadir
    Ergin, Mehmet
    Kilinc, Ibrahim
    Karaibrahimoglu, Adnan
    Colak, Tamer
    Tuncar, Alpay
    Dundar, Zerrin Defne
    Kocak, Sedat
    Girisgin, Abdullah Sadik
    Gul, Mehmet
    Cander, Basar
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (06) : 1175 - 1181
  • [27] Soluble urokinase plasminogen activator receptor (suPAR) for monitoring inflammatory activity in rheumatic diseases
    Toldi, G.
    Szalay, B.
    Kadar, G.
    Bocskai, M.
    Deak, M.
    Kovacs, L.
    Vasarhelyi, B.
    Balog, A.
    WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126
  • [28] Evaluation of plasma soluble urokinase plasminogen activator receptor (SuPAR) levels in ulcerative colitis
    Yilmaz, Huriye Erbak
    Aksun, Saliha
    Gunay, Sueleyman
    Elmali, Ferhan
    Cekic, Cem
    ARAB JOURNAL OF GASTROENTEROLOGY, 2023, 24 (03) : 175 - 179
  • [29] The levels of soluble urokinase plasminogen activator receptor (suPAR) in saliva are influenced by acute stress
    Fernandez-Botran, Rafael
    Szabo, Yvette Z.
    Lyle, Keith B.
    Newton, Tamara L.
    BIOLOGICAL PSYCHOLOGY, 2021, 165
  • [30] Soluble urokinase plasminogen activator receptor (suPAR) and glomerular disease in children: a narrative review
    Phuong Anh Le Thy
    Thuy Yen Hoang Thi
    Kiem Hao Tran
    Huu Son Nguyen
    EGYPTIAN PEDIATRIC ASSOCIATION GAZETTE, 2022, 70 (01)